

# Global Innovator in Liver Disease Therapeutics

## The Company

Promethera Biosciences' mission is to apply its proprietary liver cell-based therapeutics and complimentary biological technologies to meet the needs of patients with acute and chronic liver diseases. The company is pioneering the development of cell-based therapies that provide both immunomodulatory and anti-fibrotic effects in the liver.

The company's lead clinical program is derived from a patented allogenic liver cell platform called HepaStem. Currently in a Phase IIa clinical trial to treat patients with Acute-on-Chronic Liver Failure (ACLF), the program has the potential to target other severe and more prevalent chronic liver diseases such as Non-Alcoholic Steatohepatitis (NASH).

Promethera has developed its cell therapy technologies by using allogenic stem and progenitor liver cells. These are isolated, purified and expanded from healthy human livers unsuitable for transplantation. The process for developing these cells into a medical treatment enables the delivery of the cells to patients directly at point of care.


Promethera has strengthened its development portfolio in 2018 through the acquisition of the Swiss biopharmaceutical company Baliopharm AG. As part of the transaction, Promethera added a complimentary therapeutic strategy to its portfolio of severe liver disease medicines by selectively targeting the TNF-alpha receptor 1 (TNF-R1) and is currently preclinically developing the novel antibody-based monovalent drug candidate Atrosimab towards clinical trials in NASH/Fibrosis indication.

The company was founded in 2009 by Etienne Sokal, Promethera Biosciences' CISO and Professor of medicine at the Université Catholique de Louvain. It is located within the Walloon

healthcare cluster, Biowin, in Belgium. The Walloon region is internationally known for excellence in cell therapy research and is actively supporting Promethera. In 2016, Promethera acquired Cytonet's key assets, including its US facility based in Durham, North Carolina at the heart of the Research Triangle Park (RTP), an important center for medical research and innovation in the USA. The acquisition brought a state-of-the-art production facility in the US as well as a powerful network for sourcing ethically-donated human livers from US OPO's (Organ Procurement Organizations) to complement the cGMP facilities and tissue procurement centers in Belgium / UE along with additional experienced leadership and talents.

Since inception, Promethera has garnered the support of blue chip venture and corporate venture funds (cfr. page 2) including strategic Japanese and Korean investors, further enabling Promethera's vision of treating patients worldwide.

Disease-centrality of the liver will make it a key intervention target for novel treatments



## Product Development Pipeline

TECHNOLOGIES	INDICATIONS	R&D	PRE-CLINICAL	PHASE I	PHASE II (A / B)	PHASE III	MA/NDS
Cell therapies							
<b>HepaStem</b>	ACLF (IM)	→					
<b>HepaStem</b>	NASH/Fibrosis	→					
<b>H2Stem</b>	Regenerative Medicine	→					
<b>Heparesc</b>	Urea Cycle Disorder (UCD)	→					
Biologicals							
<b>Atrosimab</b>	NASH/Fibrosis	→					

## At a Glance

### FOUNDED

- › February 12, 2009
- › Acquisition of Cytonet GmbH & Co. KG key assets April 15, 2016
- › Acquisition of Baliopharm AG, April 10, 2018

### MANAGEMENT

- › John Tchelingierian, PhD - President & CEO
- › Etienne Sokal, MD, PhD - Chief Innovation and Scientific Officer
- › Mutsuki Takano, MBA - Group Chief Financial Officer & Branch General Manager of Promethera Biosciences Japan Branch
- › Henrik L. Luessen, PhD - Chief Business Officer
- › Mark Johnston, MBA - Chief Commercial Officer Promethera Biosciences Group and MD Promethera Biosciences LLC
- › Bertrand Lellouche - CFO EU/US Financial Operations
- › Jef Pinxteren, PhD - Vice President Operations
- › Decebal Bora, Pharm. D, MPH - Vice President Regulatory Affairs
- › Nathalie Belmonte, PhD - Vice President Product Development

### BOARD OF DIRECTORS

- › Charles L. Dimmler III, Chairman of the Board
- › Alain Parthoens (through AQ Invest BVBA)
- › Christof Hettich
- › Kinji Fuchikami
- › Masaki Doi
- › Reiko Namikawa
- › Etienne Sokal, Director A
- › John Tchelingierian, Director A (through Silver Ocean Ventures SAS)
- › Ingo Koesfeld, Observer
- › Charlie Alexander, Observer
- › Shigeru Yasue, Observer


### IP POSITION

- › 13 patent families and more than 260 patents and patent applications

### RECENT NEWS

- › October 05, 2018: Promethera Biosciences appoints Mutsuki Takano to Group Chief Financial Officer
- › August 28, 2018: cGMP Compliance Statuts for Promethera Biosciences' Production Site in Durham, NC confirmed by Health Canada
- › July 30, 2018: Promethera Biosciences Appoints Mutsuki Takano as General Manager of its Branch Office in Tokyo


## Fully-Formed Supply Chain, Production and Product Platform



## Financial Information

EUR 58M raised in equity and semi-equity since inception, not including non-dilutive support from the Walloon region of Belgium through grants and recoverable cash advances.

### MAIN INVESTORS AND SHAREHOLDERS



\* Essentially HNWI and private investors.

**PROMETHERA Biosciences SA/NV (Headoffice)**  
Watson & Crick Hill | Rue Granbonpré, 11  
B-1435 Mont-Saint-Guibert  
[info@promethera.com](mailto:info@promethera.com)

**PROMETHERA Biosciences Japan Branch (Japan Operations)**  
Tosho Building 8F | 3-8-3, Nihonbashi Honcho,  
Chuo-ku, Tokyo, 103-0023 - Japan  
[info@promethera.com](mailto:info@promethera.com)

**PROMETHERA Biosciences LLC (US Operations)**  
801 Capitola Drive | Suite 8,  
Durham NC27713 - U.S.A.  
[usteam@promethera.com](mailto:usteam@promethera.com)

**Baliopharm AG - part of the Promethera Group**  
Stänzlergasse 4  
CH-4051 Basel - Switzerland  
[info@promethera.com](mailto:info@promethera.com)

**John Tchelingierian, PhD, President & CEO**  
[John.Tchelingierian@promethera.com](mailto:John.Tchelingierian@promethera.com)

**Mutsuki Takano, MBA, Group CFO & Branch General Manager of Promethera Biosciences Japan Branch**  
[Mutsuki.Takano@promethera.com](mailto:Mutsuki.Takano@promethera.com)

[www.promethera.com](http://www.promethera.com)